ReviewPediatric nephrology (Berlin, Germany)2014
Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.
Review in Pediatric nephrology (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03776851 (Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome: a Randomized Controlled Trial
Who cites it
9 citing papers in PubMed.
- Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.Pediatric nephrology (Berlin, Germany) · 2022Trial
- De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2018Trial
- Trends in the epidemiology of paediatric kidney transplantation in Europe between 2010 and 2021: an ESPN/ERA Registry study.Clinical kidney journal · 2026Article
- Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies.Paediatric drugs · 2025Review
- Serum apolipoproteins (apoA-1, apoB, and apoB/apoA-1 ratio) for early identification of dyslipidemia in children with CKD.Pediatric nephrology (Berlin, Germany) · 2024Article
- GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease.Italian journal of pediatrics · 2023Article
- Persistent Increase in Serum Ferritin Levels despite Converting to Permanent Vascular Access in Pediatric Hemodialysis Patients: Pediatric Nephrology Research Consortium Study.Journal of clinical medicine · 2023Article
- Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review.Clinical kidney journal · 2022Review
- Chronic kidney disease in children.Clinical kidney journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia management is an important component of the care provided to children with chronic kidney disease (CKD) and influences both morbidity and mortality risk. The introduction of recombinant human erythropoietin to the treatment regimen three decades ago revolutionized the therapy and significantly decreased the need for repeated blood transfusions and exposure to associated risks. Recent data on the efficacy and complications associated with erythropoietic-stimulating agent (ESA) usage has, however, prompted a reassessment of treatment-related recommendations. This review will address these recommendations, in addition to describing pediatric outcomes associated with current ESAs and presenting information on alternative ESAs, many of which will likely soon be incorporated into clinical practice.
Indexed as
Identifiers
24005791What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.